Pharmaceutical Law & Industry Report® Index-Summary

E-HEALTH

– Consumer information, FDA and WebMD to provide, 1344
– Electronic prescriptions

– Incentives for MDs urged by HHS secretary, 636

E-PRESCRIPTIONS

– BCBS Ass'n releases key principles, 1157
– Controlled substances, DEA proposes rules, 828; opposition reported, 1122
– Fact sheet from FDA, In Brief, 1190
– Incentives for MDs

– – CMS developing rule, 1150; implements, 1261
– – Legislation

See LEGISLATION, FEDERAL, HR 4296, S 2408, S 3101

– – Payments, Analysis & Perspective, 893

– Industry/CMS conference, In Brief, 1005
– Interoperable electronic health records, e-prescribing called stepping stone, 335
– Lower-cost drugs, E-prescribing may encourage MDs, 1386
– Medicare Part D

– – Ban on computer-generated faxes of prescriptions, CMS reconsiders, 264
– – Call letter postpones deadline, 331
– – Conference planned on implementation, 855; CMS wants plans to work with pharmacies, 1093
– – PBMs push mandate, 264
– – Standards finalized, 398

– Merger of E-prescription and medical history networks planned, 776
– Safety improvements predicted, 690
– State developments

– – Governors' association supports, 832
– – La. program for Medicaid enrollees launched, 454
– – Minn. requires MDs to use e-prescribing, law signed, 688

EDETATE DISODIUM INJECTION

– Approval withdrawn, 719

EFFEXOR

– Antidepressant blamed for suicide, failure-to-warn claim preempted (W.D. Okla.), 128
– Generic

– – Approved, In Brief, 720; tentative approval, 1320
– – Patent dispute settled, generic licensed (D. Del.), 850

– Learned intermediary preempts failure-to-warn claims (5th Cir.), 544

EGYPT

– TRIPs amendments on drug access ratified, 524

ELIDEL

– Skin cream blamed for lymphoma, summary judgment granted for maker (E.D. Pa.), 823

ELOXATIN

– Chemotherapy drug, early motion allowed in infringement suit (D.N.J.), 731

ENBREL

– Arthritis drug, non-infringement motion granted (D. Del.), 1110; notice of appeal (D. Del.), 1140
– Clinical trial patients denied free continued access (9th Cir.), 419
– Immunosuppressant marketing probed by N.J. Atty. Gen., 110
– Infection risk, black box warning added, 334
– Pediatric plaque psoriasis, new indication urged by FDA panel, 749

ENTEREG

– Action letter, In Brief, 588
– Bowel function drug approved, 640
– Postoperative ileus management drug, FDA reports on benefits and risks, 131

ENTOCORT

– Barr generic ANDA challenged (D. Del.), 625
– Crohn's disease drug, Mylan ANDA for generic challenged (D. Del.), 881

ENVIRONMENTAL PROTECTION

– CFC asthma inhalers, FDA advises switch to HFA inhalers, 660
– Universal waste proposal issued by EPA, 1345

EPOETIN ALFA

– Anti-anemia drugs, FDA warns of stroke patient deaths, 1121

ERBITUX

– Application for broader indications accepted, 1270
– Cancer drug, Abbot and ImClone settle patent dispute (D. Mass.), 933

ESTRIOL

– Menopause drug restrictions

See LEGISLATION, FEDERAL, HConRes 342

EUROPEAN UNION (EU)

See also specific countries
– Aging population putting pressure on health systems, 777
– Framework for drug oversight issued, 1415
– Generics, firms accused of blocking, 1357
– Parallel imports, practice and sales limits upheld, 1067
– Research initiative launched to maintain competitiveness with U.S., 560
– Safety

– – FDA and EU approve tests, 713
– – Obstruction of inspections, drug maker probed, 668
– – Unannounced inspections of drug firms conducted, 1358

– Sector inquiry launched on drug market, 109

EVISTA

– Osteoporosis drug, stay on generic extended (S.D. Ind.), 1280

EXANTA

– Securities fraud suit over misrepresenting safety and prospects of blood thinner dismissed (S.D.N.Y.), 704

EXELON

– Alzheimer's drug, generic dispute settled (S.D.N.Y.), In Brief, 99

EXPERT WITNESSES

– Accutane product liability, expert testimony excluded, summary judgment for maker affirmed (11th Cir.), 997
– Seroquel blamed for diabetes, defense may retain treating MDs as experts (M.D. Fla.), 509
– Viagra product liability, parties challenge each others expert witnesses (D. Minn.), 18
– Zyprexa, experts may testify in wrongful death claim (Me. Super. Ct.), 602

EXUBERA

– Diabetes drug label updated to reflect lung cancer risk, 428; patients shifted to another drug, In Brief, 1064